
$VNRX: Reimbursement pathway in France in place for future sales of Nu.Q Cancer & Nu.Q NETs assays under CE Mark. Watching to see if the company achieved 2025 cash neutrality. Papers, posters & conference presentations continue to build the evidence base buff.ly/nRx9KnM

English


















